Harrow price target raised to $50 from $29 at B. Riley

B. Riley raised the firm’s price target on Harrow to $50 from $29 and keeps a Buy rating on the shares following the Q2 report. The company is well on its way to become one of the major eye care strategics, serving the high-value retina market through multiple product offerings which also serves to unlock additional inorganic growth opportunities, the analyst tells investors in a research note. The firm now sees “significantly enhanced credibility” to the company’s $500M fiscal 2027 revenue target.